Stay updated with breaking news from Nasdaq Obsv. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Let’s start up with the current stock price of ObsEva SA (OBSV), which is $2.40 to be very precise. The Stock rose vividly during the last session to $2.43 after opening rate of $2.27 while the lowest price it went was recorded $2.225 before closing at $2.21.Recently in News on December 2, 2021, O
FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant to Art....
–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the...
ObsEva Announces Year End 2020 Financial Results and Business Update March 05, 2021 01:00 ET | Source: ObsEva SA ObsEva SA Plan-Les-Ouates Geneva, SWITZERLAND -Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept- -Actively pursuing new indications and partnerships to maxi...
for Uterine Fibroids ObsEva is developing Yselty®, an oral GnRH receptor antagonist with the potential to treat more women thanks to its potential best-in-class efficacy, a favorable tolerability profile and unique, flexible dosing options for the treatment of uterine fibroids. Following the European Medicine Agency’s (EMA) recent validation of the marketing authorization application (MAA), a major milestone toward making Yselty® available in the E.U., the Company will continue to work closely with the EMA to achieve marketing approval, projected in Q4:2021. The second key objective for 2...